345 related articles for article (PubMed ID: 16048913)
1. Neopeptide antibiotics that function as opsonins and membrane-permeabilizing agents for gram-negative bacteria.
Tsubery H; Yaakov H; Cohen S; Giterman T; Matityahou A; Fridkin M; Ofek I
Antimicrob Agents Chemother; 2005 Aug; 49(8):3122-8. PubMed ID: 16048913
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of bacterial outer-membrane permeabilizers based on polymyxin B heptapeptides.
Urakawa H; Yamada K; Komagoe K; Ando S; Oku H; Katsu T; Matsuo I
Bioorg Med Chem Lett; 2010 Mar; 20(5):1771-5. PubMed ID: 20138759
[TBL] [Abstract][Full Text] [Related]
3. Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria.
Tsubery H; Ofek I; Cohen S; Fridkin M
J Med Chem; 2000 Aug; 43(16):3085-92. PubMed ID: 10956216
[TBL] [Abstract][Full Text] [Related]
4. The functional association of polymyxin B with bacterial lipopolysaccharide is stereospecific: studies on polymyxin B nonapeptide.
Tsubery H; Ofek I; Cohen S; Fridkin M
Biochemistry; 2000 Oct; 39(39):11837-44. PubMed ID: 11009595
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of Tridecaptin-Antibiotic Conjugates with in Vivo Activity against Gram-Negative Bacteria.
Cochrane SA; Li X; He S; Yu M; Wu M; Vederas JC
J Med Chem; 2015 Dec; 58(24):9779-85. PubMed ID: 26636619
[TBL] [Abstract][Full Text] [Related]
6. Colistin: an update on the antibiotic of the 21st century.
Biswas S; Brunel JM; Dubus JC; Reynaud-Gaubert M; Rolain JM
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):917-34. PubMed ID: 23030331
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the hydrophobic domain of polymyxin B nonapeptide: effect on outer-membrane permeabilization and lipopolysaccharide neutralization.
Tsubery H; Ofek I; Cohen S; Eisenstein M; Fridkin M
Mol Pharmacol; 2002 Nov; 62(5):1036-42. PubMed ID: 12391265
[TBL] [Abstract][Full Text] [Related]
8. N-terminal modifications of Polymyxin B nonapeptide and their effect on antibacterial activity.
Tsubery H; Ofek I; Cohen S; Fridkin M
Peptides; 2001 Oct; 22(10):1675-81. PubMed ID: 11587796
[TBL] [Abstract][Full Text] [Related]
9. Polymyxin B: similarities to and differences from colistin (polymyxin E).
Kwa A; Kasiakou SK; Tam VH; Falagas ME
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
[TBL] [Abstract][Full Text] [Related]
10. Polymyxin B nonapeptide potentiates the eradication of Gram-negative bacterial persisters.
Kim SJ; Jo J; Kim J; Ko KS; Lee W
Microbiol Spectr; 2024 Apr; 12(4):e0368723. PubMed ID: 38391225
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741.
Corbett D; Wise A; Langley T; Skinner K; Trimby E; Birchall S; Dorali A; Sandiford S; Williams J; Warn P; Vaara M; Lister T
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533232
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial properties of erythromycin and colistin impregnated bone cement. An in vitro analysis.
Ruzaimi MY; Shahril Y; Masbah O; Salasawati H
Med J Malaysia; 2006 Feb; 61 Suppl A():21-6. PubMed ID: 17042224
[TBL] [Abstract][Full Text] [Related]
13. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09).
Gales AC; Jones RN; Sader HS
J Antimicrob Chemother; 2011 Sep; 66(9):2070-4. PubMed ID: 21715434
[TBL] [Abstract][Full Text] [Related]
14. Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
Hansen AM; Bonke G; Hogendorf WFJ; Björkling F; Nielsen J; Kongstad KT; Zabicka D; Tomczak M; Urbas M; Nielsen PE; Franzyk H
Eur J Med Chem; 2019 Apr; 168():134-145. PubMed ID: 30807888
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains.
Alipour M; Halwani M; Omri A; Suntres ZE
Int J Pharm; 2008 May; 355(1-2):293-8. PubMed ID: 18164881
[TBL] [Abstract][Full Text] [Related]
16. Development of des-fatty acyl-polymyxin B decapeptide analogs with Pseudomonas aeruginosa-specific antimicrobial activity.
Katsuma N; Sato Y; Ohki K; Okimura K; Ohnishi K; Sakura N
Chem Pharm Bull (Tokyo); 2009 Apr; 57(4):332-6. PubMed ID: 19336926
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
[TBL] [Abstract][Full Text] [Related]
18. Emergence of polymyxin B resistance in a polymyxin B-susceptible KPC-producing Klebsiella pneumoniae causing bloodstream infection in a neutropenic patient during polymyxin B therapy.
Zavascki AP; Girardello R; Magagnin CM; Antochevis LC; Maciel RA; Palmeiro JK; Gales AC
Diagn Microbiol Infect Dis; 2018 Feb; 90(2):134-138. PubMed ID: 29150371
[TBL] [Abstract][Full Text] [Related]
19. The outer membrane permeability-increasing action of linear analogues of polymyxin B nonapeptide.
Vaara M
Drugs Exp Clin Res; 1991; 17(9):437-43. PubMed ID: 1822436
[TBL] [Abstract][Full Text] [Related]
20. Novel des-fatty acyl-polymyxin B derivatives with Pseudomonas aeruginosa-specific antimicrobial activity.
Sato Y; Shindo M; Sakura N; Uchida Y; Kato I
Chem Pharm Bull (Tokyo); 2011; 59(5):597-602. PubMed ID: 21532197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
